Search details
1.
Overall survival and objective response in advanced unresectable hepatocellular carcinoma: A subanalysis of the REFLECT study.
J Hepatol
; 78(1): 133-141, 2023 01.
Article
in English
| MEDLINE | ID: mdl-36341767
2.
Implementation of Precision Oncology in Clinical Practice: Results of a National Survey for Health Care Professionals.
Oncologist
; 28(6): e324-e330, 2023 06 02.
Article
in English
| MEDLINE | ID: mdl-36848261
3.
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: An early exploratory analysis of real-world data.
Liver Int
; 43(8): 1803-1812, 2023 08.
Article
in English
| MEDLINE | ID: mdl-37452505
4.
Clinical Significance of Molecular Subtypes in Western Advanced Gastric Cancer: A Real-World Multicenter Experience.
Int J Mol Sci
; 24(1)2023 Jan 03.
Article
in English
| MEDLINE | ID: mdl-36614254
5.
Pattern of progression of intrahepatic cholangiocarcinoma: Implications for second-line clinical trials.
Liver Int
; 42(2): 458-467, 2022 02.
Article
in English
| MEDLINE | ID: mdl-34826193
6.
Evaluation of the Molecular Landscape in PD-L1 Positive Metastatic NSCLC: Data from Campania, Italy.
Int J Mol Sci
; 23(15)2022 Aug 01.
Article
in English
| MEDLINE | ID: mdl-35955681
7.
Health-related quality-of-life impact of pembrolizumab versus best supportive care in previously systemically treated patients with advanced hepatocellular carcinoma: KEYNOTE-240.
Cancer
; 127(6): 865-874, 2021 03 15.
Article
in English
| MEDLINE | ID: mdl-33231873
8.
Serum alpha-fetoprotein and clinical outcomes in patients with advanced hepatocellular carcinoma treated with ramucirumab.
Br J Cancer
; 124(8): 1388-1397, 2021 04.
Article
in English
| MEDLINE | ID: mdl-33531690
9.
Perspectives in immunotherapy: meeting report from the "Immunotherapy Bridge" (December 4th-5th, 2019, Naples, Italy).
J Transl Med
; 19(1): 13, 2021 01 06.
Article
in English
| MEDLINE | ID: mdl-33407605
10.
Cancer Treatment-Induced Bone Loss (CTIBL): State of the Art and Proper Management in Breast Cancer Patients on Endocrine Therapy.
Curr Treat Options Oncol
; 22(5): 45, 2021 04 16.
Article
in English
| MEDLINE | ID: mdl-33864145
11.
BRAF Gene and Melanoma: Back to the Future.
Int J Mol Sci
; 22(7)2021 Mar 27.
Article
in English
| MEDLINE | ID: mdl-33801689
12.
The Enigmatic Role of TP53 in Germ Cell Tumours: Are We Missing Something?
Int J Mol Sci
; 22(13)2021 Jul 02.
Article
in English
| MEDLINE | ID: mdl-34281219
13.
Covariate-adjusted analysis of the Phase 3 REFLECT study of lenvatinib versus sorafenib in the treatment of unresectable hepatocellular carcinoma.
Br J Cancer
; 122(12): 1754-1759, 2020 06.
Article
in English
| MEDLINE | ID: mdl-32265508
14.
Ramucirumab in elderly patients with hepatocellular carcinoma and elevated alpha-fetoprotein after sorafenib in REACH and REACH-2.
Liver Int
; 40(8): 2008-2020, 2020 08.
Article
in English
| MEDLINE | ID: mdl-32279446
15.
Neck emphysema in a HNSCC cancer patient undergoing concurrent radiotherapy and cetuximab.
Rep Pract Oncol Radiother
; 25(3): 396-398, 2020.
Article
in English
| MEDLINE | ID: mdl-32322179
16.
Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial.
Lancet Oncol
; 20(1): 110-119, 2019 01.
Article
in English
| MEDLINE | ID: mdl-30522967
17.
Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet Oncol
; 20(2): 282-296, 2019 02.
Article
in English
| MEDLINE | ID: mdl-30665869
18.
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial.
Lancet Oncol
; 19(7): 940-952, 2018 07.
Article
in English
| MEDLINE | ID: mdl-29875066
19.
Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study.
Lancet Oncol
; 19(5): 682-693, 2018 05.
Article
in English
| MEDLINE | ID: mdl-29625879
20.
Phase III study with FOLFIRI + cetuximab versus FOLFIRI + cetuximab followed by cetuximab alone in RAS and BRAF WT mCRC.
Future Oncol
; 14(14): 1339-1346, 2018 Jun.
Article
in English
| MEDLINE | ID: mdl-29846100